耳廓假性囊肿前壁软骨切除术的I临床疗效观察

目的评价前壁软骨切除术对耳廓假性囊肿的治疗效果。方法耳廓假性囊肿119例，其中接受前壁软骨切除手术治疗87例（手术组），接受囊肿抽液后囊腔内注射地塞米松治疗32例（对照组），比较两组病例的治疗效果。结果所有病例随访1年以上，手术组有效率为96．6％，对照组有效率为84．4％，两组病例的有效率差异有统计学意义。结论前壁软骨切除治疗耳廓假性囊肿疗效可靠，治愈率高。     

耳廓软骨开窗法治疗耳廓假性囊肿25例体会

目的介绍耳廓软骨开窗法治疗耳廓假性囊肿的步骤、优点和操作体会。方法手术在局麻下进行,切口均选在耳廓前面,沿与耳轮大致平行方向作一贯穿囊肿之切口,将皮肤与囊肿表层软骨分离,切开囊肿表层软骨,吸净囊液,再以眼科剪将表层囊壁软骨大部分切除,以碘伏棉签轻拭囊腔,酒精棉签脱碘,缝合皮肤切口,适度加压包扎。术后换药1～2次,6～8d拆线。结果25例患者切口均Ⅰ期愈合,无感染或其它并发症。随访6～36个月,均无复发,耳廓无增厚硬化或其他畸形,外观效果满意。结论耳廓软骨开窗法治疗耳廓假性囊肿是一种疗效肯定的方法。     

微波治疗耳廓假性囊肿的疗效观察

耳廓假性囊肿是耳科常见疾病,表现为耳廓外侧面上半部的局限性肿胀,内有浆液性液体聚集形成囊肿样隆起。耳廓假性囊肿的治疗方法颇多[1,2],如抽液注药、抽液后石膏固定、冷冻治疗包扎等,疗效各有千秋。我科自1997～1999,应用珠海市和佳系统工程有限公司生产的耳鼻喉微波综合治疗仪(ＥＢＨ-Ⅲ)治疗本病,疗效满意,现报导如下。1　资料与方法1.1　一般资料　本组46例,男25例,女21例,年龄18～55岁,均单耳发病;右耳26例,左耳20例。发病后就诊时间10余天至半年,初诊34例,12例经多次穿刺注药或抽液石膏固定后无效。囊肿部位:耳廓三角窝27例,舟状窝1…     

耳廓软骨筛孔状切除法治疗耳廓假性囊肿

耳廓假性囊肿治疗方法较多 ,也较容易治疗 ,但复发性或巨大型耳廓假性囊肿 ,尚缺少较理想的治疗方法。近几年来 ,我院使用耳廓软骨筛孔状切除法治疗 2 0例 ,取得满意效果。现将资料较完整的 1 4例总结报告如下。1　临床资料1 1　一般资料　本组 1 4例 ,男 1 2例 ,女 2例 ,年龄 3 2～65岁 ,平均 45岁 ,病程 1 5ｄ～ 6个月 ,右耳 1 2例 ,左耳 2例 ,住院 7～ 3 4ｄ ,平均 1 8ｄ,耳廓囊肿最大几乎占据耳廓所有软骨部分 ,最小约蚕豆大。1 2　手术方法　患者取仰卧位 ,患耳朝上 ,常规消毒、铺巾 ,1 %普鲁卡因加少许肾上腺素行切口局部浸润麻醉 ,…     

He-Ne激光治疗耳廓假性囊肿48例疗效观察

我们采用He-Ne激光治疗耳廓假性囊肿,取得了较好效果,报道如下.     

放射性核素胶体治疗耳廓假性囊肿63例

耳廓假性囊肿的治疗一般采用穿刺抽液加压固定、腔内注射消炎药、理疗和冷冻、甚至切开引流等方法，但往往失败。自1996年以来，我科采用放射性核素弛素^32P-胶体介入治疗法，治疗耳廓假性囊肿63例，并取得满意效果，现介绍如下。     

鼻前庭囊肿与耳廓假性囊肿的开窗引流术

鼻前庭囊肿指发生于鼻前庭底部皮下、梨状孔前外方、上颌骨牙槽突骨质浅面软组织内的囊性肿块,耳廓假性囊肿又称为耳廓浆液性软骨膜炎,是发生于耳廓腹侧面的局限性囊肿,两者同属于耳鼻喉科门诊的常见病、多发病,均具有手术切除不易彻底,术后囊肿易复发的特点。我科将2008~2011年间收治的鼻前庭囊肿与耳廓假性囊肿患者随机分为实验组与对照组,观察两组患者应用不同治疗方法后的疗效,现报告如下。     

耳廓假性囊肿激光治疗与常规治疗对比观察

耳廓假性囊肿激光治疗与常规治疗对比观察秦兆冰程秀莲董明敏我们采用ＮｄＹＡＧ激光治疗耳廓假性囊肿３０例，并与手术治疗组和穿刺抽液组各３０例对比观察，现将结果报告如下：临床资料和方法患者共９０例，男５２例，女３８例；年龄１８岁～５４岁。囊肿位于左耳者４９...     

地塞米松囊内注入治疗耳廓假性囊肿

耳廓假性囊肿是常见病 ,由于病因不明 ,治疗的方法较多 ,各有其特点。笔者根据临床实践认为 ,地塞米松囊内注入法治疗耳廓假性囊肿 ,具有安全、简便、费用低、病人痛苦小、效果良好等优点 ,值得临床推广应用。1　临床资料　　自 19871999年共治疗 72例 ,男 6 1例 ,女 11例 ,年龄 4 72岁 ,平均年龄 34岁。左耳 38例 ,右耳 34例。病变在三角窝处 2 0例 ,耳甲腔 5 2例 ,抽出积液量 0 .5 3 .0ｍｌ,液体均为淡黄色。2　治疗方法　　病人坐位 ,2 %碘酒消毒病变处皮肤 ,再用 75 %乙醇脱碘 ,于囊肿上方进针 ,抽尽积液 ,保留针头于囊内 ,再向囊内注入…     

准分子激光角膜屈光手术对不同类型屈光不正的矫治效果

目的 评价准分子激光角膜屈光手术对各种类型屈光不正的矫治效果。方法 使用Keratom-F/Schwind准分子激光治疗仪对3221只不同类型的屈光不正眼行角膜光学屈光切削术或角膜原位磨镶术。随访8个月到3年。比较术前术后裸高力变化程度和观察手术并发症种类及发生率。结果 全部3221只眼术后裸眼视力达到术前矫治最佳视力为76％，小于50％最佳矫正视力仅占0.4%。近视组术后裸眼视力达到术前最佳视力为77％，远视组30cm近视力为88.2%，散光组为53.8%。并发症总发生率0.34%，包括角膜雾浊、各种角膜瓣并发症、眼底出血、视网膜脱离。结论 准分子激光手术有效提高屈光不正眼的裸眼视力。绝大多数近视，远视，散光的患者经治疗后可以达到无需眼镜正常生活和工作的目的。准分子激光手术并发症少，是一种低风险屈光矫治手术。     

Clinical Outcomes following Percutaneous Urinary Diversion for Hemorrhagic Cystitis

Hemorrhagic cystitis (HC) can lead to severe morbidity in treatment-refractory cases. Percutaneous nephrostomy (PCN) drainage was first described in 1993 as a safe, nonoperative procedure to achieve supravesical urinary diversion and treat severe HC. Despite its early success, subsequent studies in the adult population have been limited. This retrospective case series describes long-term outcomes following PCN placement in 24 patients with refractory HC. The overall technical success of the procedure was 100%. Seventeen of 24 (71%) patients experienced resolution of hematuria. The median time for hematuria resolution after the procedure was 12 days (interquartile range, 7–28 days). Postprocedural HC severity grade significantly decreased from a median Grade 3 to Grade 1 (P < .01). The complications included catheter obstruction, dislodgement, and associated urinary tract infections occurring at rates of 1.0, 1.6, and 1.7 per 1,000 catheter days, respectively. This study of PCN placement demonstrated and further confirmed the effectiveness of urinary diversion in treating refractory HC.     

Clinical Outcomes of Transcatheter Arterial Embolization for Secondary Stiff Shoulder

PurposeTo assess the clinical outcomes of transcatheter arterial embolization (TAE) for secondary stiff shoulder (SSS).Materials and MethodsThis is a retrospective analysis of prospectively collected data performed between January 2017 and December 2019. This study comprised 25 patients (20 women and 5 men; median age, 49 years; range 27–59) with SSS resistant to conservative management during at least 3 months. The median time of stiffness was 12 months. The etiology of SSS was postoperative in 14 patients (56%) and posttraumatic in the remaining 11 patients (44%). Periods of immobilization in all patients were associated. TAE was performed, and technical aspects, adverse events, changes for pain, and physical examination before and 6 months after TAE were assessed.ResultsAbnormal vessels were observed in 20 of 25 (80%) of the procedures. Transitory cutaneous erythema was noted in 4 patients treated after TAE. Significant differences were observed in the median pain visual analog scale reduction between before and 6 months after TAE (8 vs 2, P < .001). Shoulder mobility significantly improved in both flexion and abduction degrees between before and at 6 months after TAE in (70° vs 150°; P < .001). No symptoms of recurrence appeared.ConclusionsTAE can result in pain reduction and mobility improvement in patients with SSS refractory to conservative therapy.     

Pseudocyst of the pancreas in childhood

Pancreatic cysts are uncommon in childhood. Over half of those reported are caused by trauma. A case report is presented and the management of this patient discussed with reference to information from previous reports.     

腹腔镜手术与经腹手术治疗早期子宫内膜癌的效果比较

目的通过对早期子宫内膜癌腹腔镜手术治疗与经腹手术治疗效果的比较,评价腹腔镜手术治疗的临床效果。方法对2006年6月—2007年10月60例子宫内膜癌患者应用腹腔镜手术治疗(A组),并与同期60例子宫内膜癌患者应用经腹手术治疗(B组)进行比较其手术时间,平均住院天数,术后放化疗,术后并发症,2、5年复发率和生存率的差别。结果两组患者的年龄、绝经状态、肿瘤分期和组织类型比较,差别均无统计学意义(P>0.05)。两组患者术后放化疗、2、5年复发率和生存率比较,差别无统计学意义(P>0.05);A组手术时间短,住院天数少,术后并发症少(P<0.05)。结论在掌握手术指征的情况下,腹腔镜手术治疗子宫内膜癌具有良好的疗效。     

Intermediate to Long-Term Clinical Outcomes of Percutaneous Cryoablation for Renal Masses

PurposeThe purpose of this study was to evaluate the effectiveness and adverse outcomes of percutaneous cryoablation (CA) for treatment of renal masses in a large cohort of patients.Materials and MethodsThis retrospective analysis included 299 CA procedures (297 masses in 277 patients) performed between July 2007 and May 2018 at a single institution. The mean patient age was 66.1 years (range, 30–93 years) with 65.8% being male. A total of 234 (78.8%) masses were biopsy-proven renal cell carcinoma (RCC). The mean maximal tumor diameter was 2.5 cm (range, 0.7–6.6 cm). Efficacy was assessed only for ablations of biopsy-proven RCC, whereas the evaluation of adverse events and renal function included all masses. Complications were graded according to the Society of International Radiology classification.ResultsMajor complications occurred in 3.0% of procedures (n = 9), none of which resulted in death or permanent disability. The mean imaging follow-up period was 27.4 months (range, 1–115) for the 199 RCC patients (204 ablated tumors) with follow-up imaging available. Complete response on initial follow-up imaging at mean 4.2 months (range, 0.3–75.6) was achieved in 195 of 204 tumors (95.6%) after a single session and in 200 of 204 tumors (98.0%) after 1 or 2 sessions. Of the RCC patients achieving complete response initially, local recurrence during the follow-up period occurred in 3 of 200 tumors (1.5%). Metastatic progression occurred in 10 of 193 (5.2%) RCC patients without prior metastatic disease during follow-up.ConclusionsCA for renal masses is safe and remains efficacious through intermediate- and long-term follow-up.